Diabetes

This lifetime economic analysis demonstrates vagal nerve blocking therapy to be a cost-effective alternative to conventional therapy in class 2 and 3 obesity patients.

Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.

This week, the top stories in managed care include a study on which mammogram recommendations to follow; findings that continuous glucose monitoring benefits patients with type 2 diabetes; and a new position statement on treating patients with diabetes and hypertension.

Researchers have outlined a 6-item risk stratification tool that successfully predicted the likelihood that patients with diabetes will have a hypoglycemia-related emergency department visit or hospital admission.

A Dexcom spokeswoman said there are already 20,000 Medicare patients in the pipeline with almost no advertisement of the policy change.

The American Diabetes Association (ADA) today offered a position statement on treating diabetes and hypertension for the first time since 2003.

Children who were obese or at risk of obesity had less activity in the brain's self-regulation centers.

To avoid bias, the study did use aggressive titration protocols that might be found in a real-world setting. Still, patients using CGM saw greater reductions in A1C and more time in range.

A cardiovascular outcomes trial has already shown a reduction in cardiovascular events, but not deaths.

The findings suggest identifying children at risk of T2D and fixing their sleep could be a low-cost way to head off type 2 diabetes.

Cardiologists were thrilled with results of the FOURIER trial, but payers were less moved. Given the drug's $14,000 a year price, some wanted to know if they would see more than the 30% to 35% discounts they had been offered.

Those in the lowest income category had consistently light levels of activity, the study found.

Patient reported data can be a reliable source of information to ascertain comorbidities in patients with prostate cancer, says JAMA Oncology study.

The connection between diabetes and cardiovascular disease is well-known, but a new study gets at the mechanism of how this occurs.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This week, the top managed care stories included a look at the politics of right-to-try legislation; the success of FDA's expedited review programs; and a review on the best way to prevent cardiovascular risk in patients with diabetes.

Technology, new standards for diabetes education and support, and data-sharing were themes of this year's annual meeting of the American Association of Diabetes Educators.

New research indicates that veterans who played a diabetes education game in teams demonstrated greater improvements in blood glucose control than veterans who learned about diabetes management from a booklet.

The discovery capitalizes on years of work to understand immune system pathways that lead to the destruction of beta cells in type 1 diabetes.

Two clinical-community interventions-enhanced primary care and enhanced primary care with coaching-are capable of improving parent-reported outcomes and a child's quality of life for childhood obesity.

The review reports that fewer than 50% of patients with diabetes are being treated according guidelines to prevent a cardiovascular event.

Coverage from the 2017 meeting of the American Association of Diabetes Educators.

Coverage from the 2017 meeting of the American Association of Diabetes Educators.

Coverage from the 2017 meeting of the American Association of Diabetes Educators.

Coverage from the 2017 meeting of the American Association of Diabetes Educators.